Inhalation Sciences signs extension of leasing agreement with Karolinska Institutet worth 100 000 SEK

Report this content

(Stockholm, 19 November 2021) The Institute of Environmental Medicine (IMM) at Karolinska Institutet has extended its lease of ISAB’s aerosol generation platform PreciseInhale ®. The extended lease lasts for the first half of 2022 and includes ISAB’s innovative new in vivo module for aerosol exposures to guinea pigs. IMM is one of the world’s most innovative pulmonary research bodies, and a returning ISAB customer. The original agreement was signed and announced in March 2020.

The extended lease includes ISAB’s new in vivo module for aerosol exposures to guinea pigs. Guinea pigs are a highly relevant test subjects for inhalation studies. Human and guinea pigs share many similarities in lung anatomy, physiology, pharmacology, particularly airway autonomic control and response to allergens.

The new module employs ISAB’s unique one-animal-at-a-time precision dosing method – with single animals being gently dosed through a controlled exposure, generating high-precision data and reducing the need for large numbers of test animals. The guinea pig module is attracting interest from several other customers.

The extended lease is between ISAB and IMM Associate Professor Mikael Adner, Head of the Unit for Experimental Asthma and Allergy Research, a leading expert in pulmonary research and the author of over 100 peer-reviewed papers. Assoc Professor Adner: “We have recently developed a unique guinea pig asthma model where we use relevant allergens and exposure through the airways. With the PreciseInhale® we will be able to deliver aerosol with even lung distribution that also reaches the peripheral parts. This will be an important tool in our asthma research. “

ISAB CEO Manoush Masarrat: “Karolinska Institutet is a much-valued, long-term customer and we are pleased to continue our agreement with them. The fact that customers of this calibre keep returning speaks clearly to the exceptional value and precision of our tools.”

For more information about Inhalation Sciences, please contact:

Manoush Masarrat, CEO


Mobile: +46 (0)73 628 9153

About Inhalations Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company’s patented lab instruments PreciseInhale® and DissolvIt® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.

The information above was provided by Inhalation Sciences Sweden AB according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on November 19, 2021.